Lucentis And Avastin Stack Up In CATT, Forcing Genentech/Novartis To Play Defense
This article was originally published in The Pink Sheet Daily
The efficacy of low-cost Avastin and pricier Lucentis for the treatment of wet-AMD are similar in the first head-to-head clinical trial to compare the two drugs, though Novartis and Genentech call out safety uncertainties.
You may also be interested in...
Observational cohort data suggest infection risk is lower with off-label use of compounded Avastin than with Genentech's approved ophthalmic treatment, Lucentis, although not statistically significant.
The first head-to-head comparison of Eylea, Avastin and Lucentis in diabetic macular edema shows a superior benefit for Eylea in patients with more advanced vision loss and that Avastin is as effective as the other two drugs in other patients.
Ophthalmologists are among the highest billing specialties listed in the Medicare Part B physician payment data, with Genentech’s Lucentis a strong driver of cost.